Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Glioma in 2014

Unravelling tumour heterogeneity—implications for therapy

Nature Reviews Clinical Oncology volume 12, pages 69–70 (2015)Cite this article

Subjects

Heterogeneity within and across tumours is increasingly recognized as a critical factor that limits therapeutic progress for many cancers. Key studies reported in 2014 describe previously unappreciated patterns of geographical and temporal heterogeneity for glioblastoma (the most-common primary CNS tumour in adults), with important implications for ongoing therapeutic studies evaluating molecular targeted therapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189–193 (2014).

    Article  CAS  PubMed  Google Scholar 

  3. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).

  4. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Taal, W. et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 15, 943–953 (2014).

    Article  CAS  PubMed  Google Scholar 

  7. Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709–722 (2014).

    Article  CAS  PubMed  Google Scholar 

  8. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699–708 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).

    Article  CAS  PubMed  Google Scholar 

  10. Phillips, H. S. et al. Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]) [abstract]. J. Clin. Oncol. 32 (Suppl.), a2001 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Neuro-Oncology, Dana–Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, 02215, MA, USA

    David A. Reardon & Patrick Y. Wen

Authors
  1. David A. Reardon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Y. Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Reardon.

Ethics declarations

Competing interests

D.A.R. has served as a consultant and received honoraria from Amgen, Apogenix, EMD Serono, Genentech/Roche, Merck/Schering-Plough, Momenta Pharmaceuticals, Novartis and Stemline Therapeutics. P.Y.W. has served as a consultant and received honoraria from Abbvie, Celldex, Foundation Medicine, Genentech/Roche, Novartis, Momenta Pharmaceuticals and Sigma Tau.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reardon, D., Wen, P. Unravelling tumour heterogeneity—implications for therapy. Nat Rev Clin Oncol 12, 69–70 (2015). https://doi.org/10.1038/nrclinonc.2014.223

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.223

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer